Palatin, King Report Positive Results of Phase IIa Pilot Study of PT-141

Palatin Technologies and King Pharmaceuticals have announced positive results of a Phase IIa pilot clinical study evaluating PT-141 in premenopausal women diagnosed with female sexual dysfunction (FSD).

Patients in the study receiving PT-141 reported increases in their levels of sexual desire and genital arousal compared to placebo. Additionally, there was a correlation between sexual desire and genital arousal in patients receiving PT-141, an observation that further reinforces the potential importance of these reports.

Eighteen women with a diagnosis of FSD were enrolled in this double-blind, randomized, placebo-controlled, single-dose, cross-over clinical study. All patients completed a Treatment Satisfaction Index at 24-hours postdose as a means of measuring their levels of sexual desire, genital arousal and, if applicable, satisfaction with sexual intercourse. Adverse events reported include nausea, headache and nasal congestion.